文献速递浆细胞疾病

伊贝度胺、伊沙佐米和地塞米松治疗首次复发的老年多发性骨髓瘤患者

Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse.
PubMed 文献 · Br J Haematol · 2025-01-05

这项2期研究评估了口服三联方案伊贝度胺、伊沙佐米和地塞米松(I2D)在70岁及以上首次复发多发性骨髓瘤患者中的疗效与安全性。共入组70例患者,中位随访14个月,总缓解率64%,12个月无进展生存率52%、缓解持续时间76%、总生存率86%,最常见3-4级毒性为中性粒细胞减少(46%)。

要点

  • I2D方案在≥70岁首次复发MM患者中总缓解率64%,≥非常好的部分缓解率36%。
  • 12个月无进展生存率52%、缓解持续时间76%、总生存率86%。
  • 最常见3-4级毒性为中性粒细胞减少(46%),非血液学不良事件多为1-2级。

核心结论

  • I2D在老年首次复发MM患者中显示出有利的风险-获益特征,包括来那度胺和达雷妥尤单抗难治的患者。

研究设计与样本

  • Intergroupe Francophone du Myélome的2期研究(NCT04998786),评估口服三联伊贝度胺、伊沙佐米和地塞米松(I2D)在≥70岁首次复发MM患者中的疗效。
  • 共入组70例患者,接受伊贝度胺1.6 mg第1-21天、伊沙佐米3 mg第1、8、15天、地塞米松20 mg第1、8、15、22天(第1-2周期)和10 mg第1、8、15、22天(第3-6周期),28天为一周期,直至疾病进展。
  • 中位年龄76岁;50%患者根据国际骨髓瘤工作组衰弱评分判定为衰弱;74%和37%分别对来那度胺和达雷妥尤单抗难治。

主要发现

  • 中位随访14个月,总缓解率64%,包括36%非常好的部分缓解或更好。
  • 12个月无进展生存率52%、缓解持续时间76%、总生存率86%。
  • 最常见(46%)的3-4级毒性为中性粒细胞减少;非血液学不良事件大多为1级或2级。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most transplant-ineligible patients present with multiple myeloma (MM) refractory to lenalidomide and/or anti-CD38 monoclonal antibody at first relapse and represent a difficult-to-treat population. The Intergroupe Francophone du Myélome phase 2 study iberdomide, ixazomib and dexamethasone (I2D) evaluated the oral triplet iberdomide, ixazomib and dexamethasone in MM patients aged ≥70 years at first relapse (NCT04998786). Seventy patients were enrolled to receive iberdomide (1.6 mg on day 1-21), ixazomib (3 mg on day 1, 8, 15) and dexamethasone (20 mg on day 1, 8, 15, 22 on cycle 1-2 and 10 mg on day 1, 8, 15, 22 on cycle 3-6) (28-day cycle) until disease progression. Median age was 76; 50% patients were frail according to the International Myeloma Working Group frailty score; 74% and 37% were refractory to lenalidomide and daratumumab respectively. With a median follow-up of 14 months, the overall response rate was 64%, including 36% very good partial response or better. The 12-month progression-free survival, duration of response and overall survival were 52%, 76% and 86% respectively. The most common (46%) grade 3-4 toxicity was neutropenia. Non-haematological adverse events were mostly grade 1 or 2. Overall, I2D demonstrated a favourable risk-benefit profile in elderly MM patients at first relapse, including in patients with lenalidomide and daratumumab refractory disease.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Touzeau C, Leleu X, Tiab M, et al. Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse. Br J Haematol. 2025. PMID: 39757748. doi:10.1111/bjh.19978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。